February 12, 2024

Long-Term Outcomes of Mitral Valve Repair for Degenerative MR Worse in Women Than Men

A call for surgical guidelines to adopt sex-specific thresholds of LV size and function

illustration of mitral valve with male/female symbol overlay

By the time women with degenerative mitral regurgitation (MR) meet recommended thresholds for surgical repair, they are more likely than men to have more frequent and severe symptoms, atrial fibrillation and a higher left ventricular end-systolic diameter indexed to body surface area (LVESDi). Additionally, after surgery, they have worse long-term mortality than their male counterparts.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

So found a retrospective cohort study of more than 4,500 patients who underwent isolated mitral valve (MV) repair for degenerative MR at Cleveland Clinic, recently published in the Journal of the American College of Cardiology (2024;83[2]:303-312). The authors call for consideration of revising surgical guidelines with sex-specific thresholds so that women may be recommended for MV repair surgery earlier.

“Although women and men had similar absolute systolic dimensions at the time of surgery, when indexed to body surface area, women’s dimensions were significantly larger,” says corresponding author Leslie Cho, MD, Director of Cleveland Clinic’s Women’s Cardiovascular Center. “It’s no surprise that women’s outcomes after mitral valve repair are less good than men’s since women are being operated on with more advanced disease.”

Guidelines make no sex-specific distinctions

Current American College of Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology guidelines have uniform thresholds related to cardiac size and function when determining candidacy for MV repair. Current ACC/AHA Class I recommendations for surgery for severe MR are symptomatic disease, an LVESD of at least 4.0 cm and an LV ejection fraction of less than 60%.

However, notes Dr. Cho, it is well recognized that there are important differences between men and women with severe MR. “At similar levels of clinical severity, women tend to have smaller cardiac dimensions than men, so they tend to be sicker by the time they meet surgical thresholds,” she says.

Although MV prolapse is more common in women than men in developed countries, women are often underrepresented in observational studies of MV interventions. This study was designed to compare long-term all-cause mortality between men and women following MV repair for isolated degenerative MR with respect to baseline measures of LV size and function.

Advertisement

Study cohort and comparisons

All patients underwent isolated MV repair for degenerative MR at Cleveland Clinic between 1994 and 2016. Of 4,589 patients analyzed, 40% (n = 1,825) were women and 60% (n = 2,764) were men. Over median follow-up of 7.2 years, 344 deaths (7.5%) occurred across the cohort.

At baseline, women and men were of similar age, had similar levels of MR and tricuspid regurgitation, had a similar ejection fraction (mean of 59%) and had similar LVESD measures. However, the following key significant differences were found:

  • Women more often had comorbidities, including atrial fibrillation (22.9% vs. 18.6%; P = .001) and cerebrovascular disease (7.1% vs. 4.8%; P < .001).
  • Women were likelier to be classified in New York Heart Association class III or IV (37.6% vs. 23.2%; P < .001).
  • Women had a larger LVESDi (1.9 cm/m2 vs. 1.7 cm/m2; P < .001).

Important differences in outcomes were also identified:

  • All-cause mortality during follow-up trended higher in women (hazard ratio [HR] = 1.16; 95% CI, 0.96-1.40).
  • Mortality increased for patients below the LVESD surgical threshold of 4.0 cm among women (i.e., at 3.6 cm) but not among men.
  • Mortality risk increased at an LVESDi of 1.8 cm/m2 for women versus 2.1 cm/m2 for men.
  • Mortality increased above baseline at an ejection fraction of 58% in both men and women, but as ejection fraction decreased below that level, mortality increased more sharply in women.

Findings support consideration of guideline changes

With higher ejection fractions and smaller cardiac sizes than men at similar levels of disease severity, women with MR are less likely to meet thresholds for MV repair under current guidelines.

“Women were found to have higher rates of long-term mortality for the same preoperative ventricular dimensions adjusted to body size as men, and for the same ejection fractions,” Dr. Cho observes.

Advertisement

She emphasizes that the study findings are strong, given the large cohort, the long follow-up period and the cohort’s uniformity in that all patients underwent isolated MV repair for degenerative MR.

“When a woman (or a man) is found to have severe mitral regurgitation on an echocardiogram, it is time to consult a surgeon,” notes study co-author A. Marc Gillinov, MD, Chair of Thoracic and Cardiovascular Surgery at Cleveland Clinic. “Waiting to fix the valve is detrimental, particularly for women. With our contemporary mitral valve repair rate of 99.8% and a risk below 0.05%, a simple operation to repair the mitral valve is clearly the patient’s best option.”

Dr. Gillinov continues: “We hope our study will prompt guideline-setting societies to consider adopting sex-specific ejection fraction and LVESDi thresholds to help determine candidacy for surgical repair to treat mitral regurgitation. The negative consequences of waiting to meet currently recommended thresholds for left ventricular dimensions and function are significantly greater for women than for men.”

An additional perspective

“There is increasing evidence that one size does not fit all in optimally timing valve intervention, and that gender and age may modify cardiac remodeling, especially in valve regurgitation,” adds Brian Griffin, MD, Section Head of Cardiovascular Imaging, who was not involved in the study. “This paper comes on the heels of prior evidence from our group that women with aortic regurgitation also may benefit from intervention at lower left ventricular size than men. Awareness of these gender differences is important in ensuring the best possible long-term outcomes for patients with these common and very treatable valve lesions.”

Related Articles

23-HVI-4424566_mitral-valve_650x450
December 13, 2023
Study Reveals Persistence of Later Surgical Referrals for Severe Degenerative Mitral Regurgitation

While mortality was unaffected, later surgery was associated with more reoperations

23-HVI-4417336 CQD 650&#215;450
December 12, 2023
Aortic Valve Reimplantation Shows Long-Term Durability in Patients With Connective Tissue Disorders

Many young patients can avoid lifelong anticoagulation with a valve-sparing approach

illustration of mitral valve transcatheter edge-to-edge repair
December 1, 2023
The Two FDA-Approved M-TEER Systems Are Comparable at 1-Year Follow-Up, CLASP IID Data Show

And substudy reveals good outcomes with PASCAL system in patients with complex mitral valve anatomy

illustration of tricuspid valve regurgitation
November 10, 2023
TRILUMINATE Health Status Analysis: T-TEER Patients Likelier to Be ‘Alive and Well’ at 1 Year

Investigators conclude that improved self-reports go beyond possible placebo effect for severe TR

23-HVI-4298711_TAVR-vs-SAVR_650x450
November 1, 2023
TAVR and SAVR Perform Similarly at 5 Years in Low-Risk Patients, PARTNER 3 Report Shows

Five-year data demonstrate convergence of outcomes from years 1 to 5

illustration of aortic stenosis suggesting sex-related differences
September 22, 2023
Study Links Sex With Progression and Outcomes of Early-Stage Aortic Stenosis

Differences in pace of hemodynamic change signal need for sex-specific management

23-HVI-4078932_severe-tricuspid-regurgitation_650x450
August 2, 2023
Early Surgery for Isolated Severe Tricuspid Regurgitation Improves Outcomes

Cleveland Clinic study argues against waiting for symptoms to develop

Blood Clot Cell Artery
May 31, 2023
PROACT Xa: Apixaban Is Not a Safe Warfarin Substitute With Mechanical Aortic Valve

Details released from the trial halted due to excessive thromboembolic events

Ad